# OH2 Oncolytic Viral Therapy in Central Nervous System Tumors

> **NCT05235074** · PHASE1,PHASE2 · RECRUITING · sponsor: **Binhui Biopharmaceutical Co., Ltd.** · enrollment: 28 (estimated)

## Conditions studied

- Central Nervous System Tumors

## Interventions

- **BIOLOGICAL:** OH2 injection

## Key facts

- **NCT ID:** NCT05235074
- **Lead sponsor:** Binhui Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-16
- **Primary completion:** 2026-06-16
- **Final completion:** 2026-06-16
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05235074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05235074, "OH2 Oncolytic Viral Therapy in Central Nervous System Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05235074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*